Patients with estrogen receptor–positive, #HER2 -negative advanced #BreastCancer experienced significantly longer progression-free survival when treated with an oral #CombinationTherapy that included #giredestrant, a next-generation selective #EstrogenReceptor degrader and complete antagonist.